Fast-Track Multimodal monitoring for neonatal neurocritical care

项目总结 在美国，大约有150万名婴儿被送入新生儿重症监护病房(NICU) 年。对这些患者进行持续监测是至关重要的，能够快速识别 患者的健康状况对指导日常护理和治疗至关重要。虽然个人医疗设备是有帮助的 在这一努力中，将来自多个设备的信息集成到一个显示器上并进行实时 对这些数据的分析增强了对患者病情变化原因的识别，而不仅仅是 情况发生了变化。持续记录并提供实时趋势和实时分析 患者状态的改变有助于优化护理决策，从而改善这一脆弱人群的结局。 在这笔赠款中，我们将在之前获得批准的VITAL SYNC多模式监视器的成功基础上再接再厉 从NICU中的100多台设备捕获并分析信息，以帮助使信息具有可操作性。 这种新设备提供了对患者病情的连续和回顾查看，因此护理人员可以 客观评价改良治疗的效果。通过身份验证提供实时帮助 患者病情的变化有助于优化新的神经保护方案。改善了对先前患者的回顾 通过趋势分析和事件标记的情况有助于跨班次变化的连续性护理。这个 第一阶段的原型设计是为了评估该工具在NICU环境中的可行性和可用性。这个 第二阶段系统将支持其他功能，包括减少连接负担和协议支持。 Centraview 2.0将成为未来模块化升级的平台，可增强临床决策支持(CDS) 在任何ICU环境中。 阶段1目标1-为新生儿神经危重护理创建多模式监护仪原型 基于现有的经验和技术，我们将设计和制作新一代床边监护仪 从UFHealth的NICU关键医疗设备收集和显示数据的系统。 阶段1目标2-评估新系统在模拟NICU中的可用性 在模拟的NICU环境中，我们将创建三个新生儿患者场景，并在 对8名NICU临床医生进行的可用性研究，包括调查以确定感知价值、可用性和接受度。 第2阶段目标1-扩展连接、增加协议遵从性并增强可用性 成功的第1期临床反馈将用于改进CentraView的功能和可用性 2.系统将增加对HIE协议的支持以及其他几个新功能，包括派生的 参数和无线数据采集。 阶段2-目标2-评估CentraView 2临床助理的效果 我们将首先在UFHealth收集6个月的基线数据，以衡量对几个临床实践的遵从性 准则(CPG)。接下来，我们将安装并培训临床医生如何使用CentraView系统，并确定 该系统提高了对CPG的遵从性。

PROJECT SUMMARY In the US, approximately 1.5M babies are admitted to the Neonatal Intensive Care Unit (NICU) each year. Continuous monitoring of these patients is essential and the ability to quickly identify critical changes in a patients' health status is crucial to guiding daily care and therapy. While individual medical devices are helpful in this endeavor, integrating information from multiple devices onto one display and performing real-time analytics on this data enhances identification of the reasons for a change in patient condition and not just that a condition has changed. Continuously recording and providing both trending and real-time analysis for real changes in patient status can help optimize care decisions thus improving outcomes in this fragile population. In this grant we will build upon the success of the previously cleared Vital Sync multi-modal monitor that captures and analyzes information from over 100 devices in the NICU to help make the information actionable. The new device provides a continuous and retrospective view of patient condition so that care providers can objectively evaluate the effectiveness of treatment modifications. Real time assistance with identification of changes in patient condition helps to optimize new neuroprotective protocols. Improved review of prior patient condition through trending analysis and event marking assists with continuity of care across shift changes. The Phase I prototype is designed to evaluate the feasibility and usability of the tool in the NICU environment. The phase 2 system will support additional features including reduced connectivity burden and protocol support. Centraview 2.0 will be a platform for future modular upgrades that will enhance clinical decision support (CDS) in any ICU environment. Phase 1 Aim 1 – Create a prototype multimodal monitor for neonatal neurocritical care Based on existing experience and technology, we will design and prototype a new generation bedside monitoring system for collecting and displaying data from the key NICU medical devices at UFHealth. Phase 1 Aim 2 – Evaluate usability of the new system in a simulated NICU In a simulated NICU environment, we will create three neonatal patient scenarios and evaluate the system in a usability study with 8 NICU clinicians including surveys to determine perceived value, usability, and acceptance. Phase 2 Aim 1 – Expand connectivity, add protocol adherence, and enhance usability Clinical feedback from a successful Phase 1 will be used to improve the functionality and usability of CentraView 2. HIE protocol support will be added to the system along with several other new features including derived parameters and wireless data collection. Phase 2 – Aim 2 – Evaluate the effectiveness of CentraView 2 Clinical Assistant We will first collect baseline data for 6 months at UFHealth to measure adherence with several clinical practice guidelines (CPG). Next, we will install and train clinicians on the use of the CentraView system and determine if the system improves compliance with the CPGs.